The Impact of Carbohydrate Antigen 19-9 on Survival in Patients with Clinical Stage I and II Pancreatic Cancer.

ABSTRACT

BACKGROUND: Carbohydrate antigen (CA) 19-9 is a biomarker to monitor treatment effect. A threshold to predict prognostic significance remains undefined. We evaluated the impact of CA19-9 on overall survival (OS) in patients with early-stage pancreatic cancer (PC) utilizing the National Cancer Database (NCDB). METHODS: The NCDB was queried from 2010 to 2014 to identify patients with clinical stage I-II PC. Patients who had undocumented pretreatment CA19-9 were excluded. Patients were stratified into two cohorts CA19-9 < 98 U/mL and CA19-9 ≥ 98 U/mL, and further categorized into surgery versus no surgery. Twelve- and 24-month OS rates are reported. RESULTS: Overall, 32,382 patients (stage I 12,173; stage II 20,209) were included. The majority of stage I (52.1%) and II (60%) patients had CA19-9 ≥ 98 U/mL. Stage I-II patients with CA19-9 < 98 U/mL had improved OS rates (stage I 67.5%, 42.6%; stage II 59.8%, 32.8%) compared with stage I and II patients with CA19-9 ≥ 98 U/mL (stage I 50.7%, 26.9%; stage II 48.1%, 22%). Among resected stage I patients, CA19-9 <98 U/mL was associated with improved OS (< 98 80.5%, 56%; ≥ 98 70.2%, 42.8%), and a similar trend was seen in resected stage II patients (< 98 77.6%, 49.9%; ≥ 98 71%, 39.2%). Unresected stage I patients with lower CA19-9 had improved OS (< 98 42.1%, 17.5; ≥ 98 29.9%, 10%), with similar findings in unresected stage II patients (< 98 41.1%, 15.3%; ≥ 98 33.4%, 10.6%). CONCLUSIONS: Our study demonstrated the prognostic value of CA19-9 in patients with clinical stage I-II PC, with a value < 98 U/mL demonstrating improved survival. Surgery significantly improved survival at 12 and 24 months irrespective of CA19-9.